Back to search results

Study of CCS1477 (Inobrodib) for Blood Cancers

This study is looking at a new oral capsule called CCS1477 (Inobrodib) for people with certain blood cancers (haematological malignancies) like acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), or higher-risk myelodysplastic syndrome. Researchers want to see how safe CCS1477 is and how well your body tolerates it, both on its own and when given with other standard treatments like Pomalidomide, Dexamethasone, Azacitidine, or Venetoclax. You might be able to join if you are 18 or older, have one of these blood cancers that has come back or not responded to previous treatments, and have good overall health. The main goal is to track any side effects and changes in lab tests for up to 12 months.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 250 participants, but the phase and status are not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track side effects and lab results for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Recruiting
PHASE1Ages 18+InterventionalTreatment
CellCentric Ltd.
~250 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:CCS1477PomalidomideDexamethasoneAzacitidineVenetoclaxBortezomib

At a glance

Recruiting sites
34 of 39 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment-related adverse events
Measured over Up to 12 months
+1 more outcome measured

Conditions

Haematological Malignancy
Acute Myeloid Leukemia
Non Hodgkin Lymphoma
Multiple Myeloma
Higher-risk Myelodysplastic Syndrome
Peripheral T Cell Lymphoma

Explore related trials

Acute Myeloid LeukemiaHematologic NeoplasmMature T-Cell and NK-Cell Non-Hodgkin LymphomaMultiple MyelomaMyelodysplastic SyndromeNon-Hodgkin Lymphoma

Where it's being run

39 sites across 10 states
United Kingdom17
Spain12
Nebraska2
France2
Georgia1
Indiana1
Maryland1
Pennsylvania1

Study leadership

  • Tim Somervaille · PRINCIPAL_INVESTIGATOR · The Christie NHS Foundation Trust

Who to contact

Tomasz Knurowski, PhD
[email protected]
07882871299
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provision of consent
ECOG performance status 0-2
Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
Must have previously received standard therapy
Adequate organ function

Exclusion

Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
Patients should discontinue statins prior to starting study treatment
CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
Any unresolved reversible toxicities from prior therapy \>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
Any evidence of severe or uncontrolled systemic diseases
Any known uncontrolled inter-current illness
QTcF prolongation (\> 470 msec)

What this trial measures

  • Incidence of treatment-related adverse eventsUp to 12 months

    Treatment-related adverse events and serious adverse events

  • Incidence of laboratory abnormalitiesUp to 12 months

    Laboratory abnormalities characterised by type, frequency, severity and timing